Kevin Tang

CEO Kevin Tang purchases 814,606 shares totaling $12,455,227.01 across 5 transactions at $15.28–$15.35

Kevin Tang, CEO of Aurinia Pharmaceuticals, made 5 separate open-market purchases totaling 814,606 shares for $12,455,227.01 between May 29 and June 2, 2026, at a blended average price of $15.29, raising his holdings from 12,229,500 to 13,044,106 shares. This represents a 6.7% increase in his pre-transaction position at a company with strong fundamentals: $77,705,000 in latest quarterly revenue, $34,355,000 net income, 20.4% annual revenue growth, and a P/E of 6.63. His prior 5 purchases at AUPH were all well-timed at the 90-day mark, establishing a consistent pattern of buy timing at this ticker. The current stock price of $15.39 reflects minimal movement from the purchase window, positioning this filing for near-term market assessment against his demonstrated buying pattern.

Director Kevin Tang purchased 900,000 shares for $12.7M across 6 transactions 2026-02-27 to 2026-03-03 at blended average price $14.10

Kevin Tang, a Director at Aurinia Pharmaceuticals, executed 6 separate purchases totaling 900,000 shares for $12,688,805.89 over a four-trading-day window between 2026-02-27 and 2026-03-03, at prices ranging from $13.90 to $14.38 with a blended average of $14.10. This transaction increased his holdings from 11,329,500 shares to 12,229,500 shares, representing a 7.9% addition to his pre-transaction stake. His prior AUPH trades show mixed timing outcomes, with 3 of 5 prior buys generating positive 90-day returns (most notably a buy on 2025-08-01 that returned +19.8% over 90 days), though two earlier purchases in March 2025 produced slightly negative 90-day results. The current stock price of $14.15 sits near the blended purchase average and is -13.6% from the 52-week high, occurring within a period of recent modest price weakness (−2.6% 30-day, −5.1% 90-day). The company's fundamentals remain solid with latest-quarter revenue of $73,468,000.00 and net income of $31,551,000.00, annual revenue growth of +20.4%, and a compressed P/E of 5.24 relative to the market cap of $1,881,539,352.85.

Director Kevin Tang bought 1,300,000 shares across 3 transactions for $13,590,000.00, raising stake by 13.0% to 11,329,500 shares at AUPH

Director Kevin Tang executed 3 separate purchases totaling 1,300,000 shares for $13,590,000.00 between August 1-5, 2025, at prices ranging from $10.12 to $11.68 and blended average $10.45. His post-transaction holdings reached 11,329,500 shares, a 13.0% increase from prior position. The current price of $11.70 sits at the 52-week high (+0.0%), and the stock has risen 54.2% over the prior 30 days and 44.3% over 90 days—periods that fully encompass these transactions. His prior 5 trades at AUPH show mixed results, with only 1 of 5 achieving positive 90-day returns; his cross-ticker track record shows 47.37% 90-day win rate and average 6.0% 90-day return. This substantive accumulation in a pharmaceutical company with annualized revenue growth of 34.0% occurs amid sharp near-term price momentum and against a background of modest prior accuracy at this ticker.

Director TANG KEVIN purchases 1,600,000 shares (1.60M) for $12,713,125.64 across 6 transactions Feb–Mar 2025, raising holdings 19.0%.

Director Kevin Tang executed 6 open-market purchases totaling 1,600,000 shares (1.60M shares) for $12,713,125.64 between February 28 and March 4, 2025, at a blended average price of $7.95, increasing his holdings by 19.0% from 8,429,500 to 10,029,500 shares. The timing of these concentrated purchases follows recent declines in his same-ticker history (three prior buys in early December 2024 showed 30-day returns of -8.2%, -5.2%, and -4.2%, with 90-day outcomes not yet measurable), and occurs while the stock trades 22.6% below its 52-week high of $10.44, though near its 30-day average (+1.6% recent movement). His cross-ticker track record shows 20 prior buys with an average 90-day return of +8.6% and a 50.00% win rate, but his three same-ticker purchases at AUPH have not yet demonstrated positive 90-day returns, and his timing history across both tracks shows 0 of 0 prior buys well-timed at the 90-day mark. The underlying business shows positive momentum (annual revenue growth +34.0%, net income $14.4M on $67.8M quarterly revenue, P/E 17.96), establishing a context of operational expansion supporting the director's decision to substantially increase his equity position.

Director Kevin Tang bought 1.20M shares over 3 days (Dec 5-9) at blended $9.02; holdings now 8.43M (+16.6%).

Kevin Tang, a director at Aurinia Pharmaceuticals, executed 3 separate purchases totaling 1,200,000 shares for $10,822,000.00 between December 5–9, 2024, at prices ranging from $8.91 to $9.09 per share (blended average $9.02). This represents a 16.6% increase to his existing position and adds meaningfully to his stake during a period when the stock is trading near its 52-week high of $9.49, with strong recent momentum (+39.2% over 90 days and +9.7% over 30 days). Notably, Tang's cross-ticker track record shows modest historical success (35.29% 90-day win rate with +2.0% average 90-day return), suggesting his prior open-market signals have not been consistently prescient. The company's fundamentals remain mixed: while it posted +31.0% annual revenue growth and recent profitability ($14.4M net income in the latest quarter), it was unprofitable over its most recent full fiscal year, leaving lingering questions about sustainability of earnings.

10% owner Kevin Tang buys 122,416 shares for $1.8M across 3 transactions, raising stake to 372K shares amid 153.6% 30-day rally.

Kevin Tang, a 10% owner of Singular Genomics, executed 3 separate purchases totaling 122,416 shares for $1,806,219.84 between September 16–18, with a blended average price of $14.75, increasing his holdings by 49.0% to 372,000 shares. The timing coincides with pronounced positive price momentum: the stock has risen 153.6% over 30 days and 74.4% over 90 days, now trading at $16.79 near its 52-week high of $18.30. However, the company remains unprofitable ($-21.3M net income) with minimal trailing-quarter revenue ($737.0K), though it posted 280.5% annual revenue growth. Tang's own cross-ticker track record shows 20 prior buys with a 30.00% 90-day win rate and average 90-day return of -1.9%, suggesting his historical purchasing decisions have not consistently outperformed the market. The magnitude and timing of this accumulation warrant examination of what conditions or information motivated a 49% position increase during an already-elevated valuation period.